CD163L1

Across TCGA pan-cancer cohorts, CD163L1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CD163L1 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CD163L1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD163L1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CD163L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	III,IV	1.000	0.468	.003	31	view →
LUAD	DFS	Quartile	All	0.778	0.427	.003	17	view →
CCRCC	DFS	Tertile	III,IV	0.833	0.288	.035	12	view →
UCEC	DFS	Median	II,III,IV	0.528	1.000	.049	4	view →
LSCC	DFS	Median	III,IV	0.930	0.635	.036	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CD163L1–PDAC (DFS)

Open the PDAC breakdown →